CJC-1295 vs Ipamorelin

CJC-1295 and Ipamorelin are not interchangeable research materials: CJC-1295 is a GHRH analogue that targets the pituitary GHRH receptor, while Ipamorelin is a growth-hormone secretagogue that acts at GHS-R (the ghrelin receptor). Because the two compounds enter the growth-hormone axis at different receptor classes, substituting one for the other in an in-vitro assay does not preserve the receptor pathway under investigation. A paired research format is technically defensible only when a protocol genuinely requires both receptor pathways to be engaged simultaneously, not as a default configuration.

A second identity issue compounds the comparison: the label “CJC-1295” does not describe a single molecular entity. In the originating pharmacology literature, CJC-1295 denotes a DAC (Drug Affinity Complex) albumin-binding conjugate of modified GHRH(1–29). Merchant catalogues frequently apply the same name to the peptide without that albumin-binding group, sometimes calling it “CJC-1295 no DAC” or aligning it with modified GRF(1–29). These are materially different structures with different exact masses and different pharmacokinetic profiles in the original reports. Before any comparison is meaningful, the exact format must be confirmed against the certificate of analysis (CoA) for the batch in hand.

This comparison explains the receptor distinction between CJC-1295 and Ipamorelin, shows why DAC and non-DAC CJC-1295 must be separated, and sets out the batch documentation to check before procurement. To confirm current commercial terms or submit a purchase enquiry, use the checkout or enquiry path on the relevant Veyvora product page. All materials and discussion on this page are for laboratory and in-vitro research use only. No human treatment, administration or dosing information is provided or implied.

A GH-releasing peptide (GHRP) is a synthetic oligopeptide studied for its activity as a growth-hormone secretagogue, a compound that stimulates growth-hormone release through receptor-mediated pathways. In strict pharmacological usage, the term GHRP refers specifically to agonists of GHS-R (the ghrelin receptor), a receptor class distinct from the pituitary GHRH receptor targeted by GHRH analogues such as CJC-1295. Research catalogues sometimes apply the phrase loosely to any GH-axis peptide, which conflates two mechanistically separate receptor classes; that usage should be avoided in laboratory methods writing.

The distinction matters for assay design: a protocol targeting GHRHR signalling requires a confirmed GHRH analogue, while a protocol targeting GHS-R requires a confirmed GHRP agonist. GHRP is a mechanism label derived from primary pharmacology literature; it is not a quality certificate, a regulatory category, or a human-use designation. Before accepting any material into a GH-axis assay, researchers should verify a batch against its certificate of analysis to confirm which receptor class the supplied sequence is designed to engage. Appropriate storage and stability guidance for research peptides should also be confirmed prior to use.

A selective GH-releasing peptide (selective GHRP) is a synthetic oligopeptide agonist of the ghrelin receptor (GHS-R, specifically the GHSR-1a subtype) that stimulates GH secretion with comparatively limited activity at other pituitary axes. Ipamorelin is classified within this ligand class on the basis of early pharmacology work, specifically Raun et al., European Journal of Endocrinology, 1998. That study reported GH secretagogue activity at GHS-R with less concomitant ACTH/cortisol and prolactin signal than GHRP-6 in the experimental systems examined, and described ipamorelin as the first selective growth-hormone secretagogue. That characterisation is a receptor-class and relative-selectivity descriptor for those specific assay conditions; it is not a warranty of selectivity in every in-vitro matrix or across every commercial lot.

What Selectivity Does and Does Not Mean for Laboratory Work

Selectivity, as used in the GHRP literature, describes a ligand’s relative preference for GHS-R over other pituitary receptors in a defined experimental system. Selectivity does not describe the purity, sequence identity or endotoxin status of any particular research-chemical batch. Material labelled “ipamorelin” may carry the correct sequence at high HPLC purity and still require orthogonal mass-spectrometry confirmation before the material can be attributed to GHS-R activity in an assay; see what HPLC purity does and does not prove for the methodological limits of area-percent data [4].

Ipamorelin acts through GHS-R, whereas CJC-1295 targets the GHRH receptor (GHRHR). Substituting one for the other does not preserve receptor identity in a GHRHR or GHS-R assay; the two compounds are mechanistically complementary, not interchangeable. The CJC-1295 + Ipamorelin research explainer covers the rationale for studying both receptor inputs in parallel.

A paired CJC-1295 and Ipamorelin format is technically defensible only when the research protocol is explicitly designed to examine activity across both the GHRH-receptor (GHRHR) pathway and the ghrelin-receptor (GHS-R) pathway simultaneously, and when each compound’s identity has been independently confirmed against its own certificate of analysis before the experiment begins.

Decision Rules for Protocol Design

The choice of format should follow the receptor question, not catalogue convention:

• GHRHR pathway in isolation: use CJC-1295 (DAC or non-DAC, specified precisely) as the sole ligand. For a well-characterised GHRH-analogue comparator with a distinct structural profile, the tesamorelin research page provides a useful reference point.
• GHS-R pathway in isolation: use Ipamorelin as the sole ligand. Introducing a GHRHR agonist alongside Ipamorelin conflates two mechanistically distinct inputs and complicates attribution of any observed signal.
• Combined pathway activity: a paired format is appropriate when the assay system, for example primary pituitary cultures expressing both GHRHR and GHS-R, requires stimulation of both receptors as independent variables. The protocol must state which receptor each compound addresses and must not treat the pairing as a single composite treatment.

No synergy claim or predictable combined outcome follows from the mechanistic complementarity of these two ligand classes. Researchers designing dual-pathway assays can find a deeper mechanism discussion in Veyvora’s CJC-1295 and Ipamorelin research explainer.

CJC-1295, Ipamorelin and all related GH-axis research peptides supplied by Veyvora are intended strictly for in-vitro laboratory research use only. They are not medicines, not authorised for human or veterinary administration, and the “research use only” label does not confer any medicinal status or regulatory approval.

In the UK, a product presented as treating or preventing disease is a medicinal product under the Human Medicines Regulations 2012 and requires MHRA authorisation [1][2]. A reagent labelled solely for laboratory and in-vitro research use, and supplied without medicinal claims, sits outside that authorisation pathway, but only where the reagent is genuinely used that way. Labelling alone does not legalise medicinal supply. EU distributors must verify whether presentation triggers Directive 2001/83/EC and whether the substance falls under REACH and CLP classification [3]. South African buyers should confirm SAHPRA status under the Medicines and Related Substances Act 101 of 1965 before importing or reselling; the applicable route for unregistered material requires independent verification with SAHPRA directly.

Pre-Order Compliance Checklist for Buyers and Distributors

Before placing an order, confirm each of the following:

• Intended application is documented as in-vitro laboratory research, not human or veterinary use
• Institutional ethics or biosafety controls are in place and recorded
• COSHH risk assessment and HSE handling controls are completed for the specific peptide
• Local import classification and any required permits have been verified for the destination country
• Resale or redistribution terms comply with the jurisdiction’s requirements for research-use-only materials
• Batch documentation, including the certificate of analysis, is retained for audit purposes
• No medicinal claims will be made in any downstream communication

Once material is received, verify a batch against its certificate of analysis before use, and consult storage and stability guidance for research peptides to confirm cold-chain conditions are maintained from receipt onwards.

Before selecting CJC-1295, Ipamorelin or a paired format, a laboratory should confirm molecular identity, batch documentation, regulatory status and cold-chain integrity. The answers below address the questions most likely to affect protocol reproducibility and procurement decisions.

Are CJC-1295 and Ipamorelin the Same Type of Peptide?

No. CJC-1295 is a GHRH-receptor agonist analogue; Ipamorelin is a GHS-R agonist. They act through different receptors on the growth-hormone axis and are mechanistically complementary, not interchangeable. Substituting one for the other does not preserve receptor identity in an in-vitro assay.

What Is a GHRH Analogue?

A GHRH analogue is a synthetic peptide designed to activate the pituitary GHRH receptor (GHRHR), mimicking the action of endogenous growth-hormone-releasing hormone. CJC-1295 is a tetrasubstituted analogue of human GHRH(1–29); the DAC-bearing version additionally binds circulating albumin to extend exposure in experimental systems.

What Is a Selective GHRP?

A GH-releasing peptide (GHRP) is a synthetic oligopeptide agonist of the ghrelin receptor (GHS-R). Ipamorelin is described in the primary literature as a selective GHRP because early experimental data indicated GH secretagogue activity at GHS-R with comparatively less stimulation of ACTH/cortisol and prolactin than earlier GHRPs. Selectivity is assay- and species-dependent and is not a warranty for every in-vitro matrix or commercial lot.

Does CJC-1295 DAC Differ From Non-DAC Material?

Yes, materially. In the primary pharmacology literature, CJC-1295 denotes the albumin-binding DAC conjugate of modified GHRH(1–29). Merchant catalogues have also labelled tetrasubstituted GHRH(1–29) without the DAC moiety as “CJC-1295 no DAC.” These are structurally distinct materials; always confirm the exact format against the certificate of analysis before use.

Does HPLC Alone Prove Identity?

No. HPLC area-percent supports chromatographic purity relative to observed peaks; it does not confirm the correct amino-acid sequence, absolute peptide content or endotoxin status [4]. Identity requires orthogonal confirmation, at minimum mass spectrometry. The what HPLC purity does and does not prove page sets out where the method’s limits lie.

What Evidence Should a Laboratory Require Before Accepting a Batch?

Require a batch-specific certificate of analysis covering: mass-spectrometry identity, HPLC chromatographic purity, a separate peptide-content or amino-acid-analysis result, stated sequence and counter-ion, and a bacterial endotoxin result when the in-vitro system is endotoxin-sensitive [4]. The batch number on the pen label must match the CoA exactly.

What Does Research Use Only Mean?

In the UK, a product presented for treating or preventing disease is a medicinal product under the Human Medicines Regulations 2012 and requires MHRA authorisation [1][2]. A reagent labelled solely for laboratory and in-vitro research use, and not presented with medicinal claims, sits outside that authorisation pathway, though the label does not legalise medicinal supply. EU distributors must verify REACH/CLP classification and Directive 2001/83/EC presentation rules [3]; South African distributors should confirm SAHPRA status under the Medicines and Related Substances Act 101 of 1965 before import or resale.

For a deeper explanation of why the two receptor pathways may be studied in parallel, the CJC-1295 + Ipamorelin research explainer provides the mechanistic context this comparison page does not repeat. To confirm current availability and the approved purchase route, visit the relevant product page on Veyvora’s site directly. All materials are supplied for laboratory and in-vitro research use only.